Brought to you by 
TaiGen Biotechnology completes Series A financing
02 Nov 2001
Executive Summary
TaiGen Biotechnology (small-molecule drug discovery focused on oncology and immunology) has completed its first of a two-tranche $48mm Series A financing. The company privately placed $24mm in stock to lead investor MPM Capital and to the Development Fund, Yuen Foo Yoong, China Development Industrial Bank, Shingkong Life Insurance, Yao Hwa Glass, the Industrial Bank of Taiwan, Hotung Group, Cheng Xin Technology Development, China Synthetic Rubber, Fujisawa, Chailease Finance, Champion Venture, and Cathay Life Insurance.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TaiGen Biotechnology completes Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice